Hip fracture is common in the elderly patients with associated high risk of venous thromboembolic complications. Pathogenic activation results in the generation of various surrogate markers in plasma. This study is designed to identify unique biomarkers in elderly patients with hip fracture using protein chip array enzyme-linked immunosorbent assay (ELISA) methods. Plasma from a randomized hip fracture study (PK-532; n ¼ 341) treated with either enoxaparin (40 mg once daily) or unfractionated heparin (UFH; 5000 IU twice daily) were collected prior to and at 1, 3, 5, and 7 days. A total of 52 samples were analyzed using proteomic surface-enhanced laser desorption/ ionization-time of flight (SELDI-TOF) mass spectrometry to identify unique biomarkers in the molecular weight range of 0 to 150 kd. Twenty-nine healthy volunteer's and pooled plasma from total hip replacement/total knee replacement patients with a unique biomarker at 11.9 kd were used as quality controls. In the 29 healthy individuals, the biomarker profile did not reveal the presence of any unique peak in comparison to the reference normal human plasma (NHP). Plasma obtained prior to surgery exhibits unique biomarkers in 4 of 52 (7.6%) of the samples. On day 1 postoperatively, 41 of 51 (80.3%) showed a distinct peak at 11.9 kd. On day 3, 43 of 49 (87.8%) patients showed the presence of this biomarker most often at its strongest intensity. In all, 22 of 44 (50%) showed this biomarker on day 5 and 4 of 23 (17.9%) on day 7. Creactive protein (CRP), tumor necrosis factor a (TNF-a), and serum amyloid A were also increased after surgery. Tissue factor pathway inhibitor (TFPI) antigen levels were increased due to the treatment modalities.
Introduction
The incidence of hip fractures worldwide in 1990 was 1.6 million, with a projected incidence in 2050 of 6.26 million. The average age of occurrence is 77 years for women and 72 years for men. Risk factors include gender, race, age, poor health, smoking and alcohol, previous fracture, or fall history. Without thromboprophylaxis treatment, patients undergoing hip fracture surgery have a high risk of developing venous thromboembolism (VTE; deep vein thrombosis [DVT] ). Approximately 40% to 60% will develop VTE in the absence of treatment, with almost 5% going on to have fatal complications. 1, 2 It has been reported that patients treated with enoxaparin show improved survival compared to patients treated with UFH in the perioperative period (À1 to 7 days). 1 Orthopedic procedures results in the release of tissue factor as well as other proteases that can lead to cellular activation and formation of unique protein fragments in circulation.
Orthopedic hip fractures in the elderly patients likely generate a unique protein biomarker profile, which may exhibit upregulated protein expression when compared with younger patients. Upregulation of inflammatory mediators and unique biomarkers that contribute to thrombogenesis can be modulated by anticoagulation with heparins and low-molecularweight heparins.
Proteomics involves the characterization and quantification of proteins from body tissues or bodily fluids. 3 The surface-enhanced laser desorption/ ionization time-of flight (SELDI-TOF) mass spectrometry uses a biologic sample, such as plasma, along with a protein-binding chip. 4 The protein-binding chip is targeted with a laser beam causing molecules from the biologic sample to be ionized and travel through a vacuum tube. Their mass-to-charge ratios are calculated based on the time of flight. The technology involving SELDI-TOF does not directly identify specific proteins; however, it is more often used to identify and observe modulation of diseaserelated biomarkers in sera as well as responses to treatment. [5] [6] [7] [8] [9] [10] Acute phase response involves the generation of various cytokines and proteins that play differing roles in modulating the inflammatory and thrombogenic processes. Cytokines such as tumor necrosis factor a (TNF-a), plasma apolipoprotein, and serum amyloid A have been studied extensively to further evaluate the acute process following such events as trauma, arthritis, or acute myocardial infarction. It has been previously reported that the acute phase protein serum amyloid A was elevated 200-fold following orthopedic trauma cases. 9 These proteins have also been shown to have binding sites for heparin/heparan sulfate. More importantly, these proteins may play a role in the pharmacodynamics and pharmacokinetics of anticoagulation drugs, specifically heparins, which are used for prophylaxis of thromboembolism. 11 The current study has been designed to profile the baseline biomarkers in elderly patients recruited in the hip fracture study via protein chip array profiles, with particular reference to upregulation of inflammatory mediators such as serum amyloid A, TNF-a, C-reactive protein (CRP), and tissue factor pathway inhibitor (TFPI). Differential regulation of these markers after prophylactic administration of either heparin or enoxaparin is measured by the circulating levels of these biomarkers identified by SELDI-TOF and by enzyme-linked immunosorbent assay (ELISA) methods.
Materials and Methods

Study Participants
The plasma samples were taken from an open prospective randomized control study, PK-532 (n ¼ 341), in which patients presenting with acute fractures of the femoral neck and/or fractures of 3 the upper third of the femur were included. The patient makeup consisted of female and male participants that were treated with either enoxaparin (40 mg once daily) or UFH (5000 IU twice daily). Blood samples were collected prior to surgery and at days 1, 3, 5, and 7 postsurgery and frozen at À70 C. 1 All participants were older than 18 years of age. The average age for the group receiving enoxaparin was 77.1 (+10.1) with 39% of these patients being male. In the UFH group, the average age was 75.5 (+12.7) with 51% of the patients being male. 1 These samples were sent to Loyola from the Department of Orthopaedics, Arhus University Hospital, Arhus; Copenhagen University Hospital, Hillerad; and Aalborg University Hosptial, Aalborg, Denmark.
The patients chosen for this current study were selected at random. The goal of this study was to screen this patient population for any possible biomarkers seen in previous orthopedic studies. 12 For this reason, only 52 patients were analyzed. The samples were initially divided in their perspective enoxaparin and UFH groups. This was the only available information on the subdivision of these samples. From there, the samples were selected at random at equal numbers for the 2 groups.
As a positive control, biomarker data were compared from a previous study involving plasma collected in patients during total knee replacement and total hip replacement that contained a unique biomarker at 11.9 kd. 12 An additional 29 plasma samples (12 males, 17 females) from normal human volunteers were obtained along with a previously collected pool of normal human plasma (NHP). All plasma samples were stored at À70 C. Prior to analysis, these samples were thawed and mixed well at room temperature.
Surface-Enhanced Laser Desorption/ Ionization Time-of Flight Mass Spectrometry
Two microliters of plasma samples were diluted 1:10 in 0.1 mol/L Tris HCl, pH 7.5. From each of these mixtures, a 5-mL aliquot was then mixed thoroughly with 10 mL of energy-absorbing molecular solutions, 5 mL (sinapic acid 98% titration, acrylonitrile 100%, and trifluoric acid 0.1%). From this final solution, 5 mL was then placed on the proteomic gold chip. The chip was dried for 30 minutes prior to loading the Ciphergen/BioRad PBS II reader (Freemont, California). After the sample is loaded into the Ciphergen Biosystems/BioRad instrument, a laser is then used to target the chip, which results in the ionization of adherent molecules from the sample. Based on the time of flight through the vacuum chamber, the mass-to-charge ratios of these ions were calculated. The protein chip profiling spectra from the serum samples were collected and analyzed by CiphergenProteinChip/BioRad Software. 4 The mass range of 5 to 150 kd was analyzed, with molecules from 0 to 5 kd being eliminated because artifacts produced by the energy-absorbing molecule as well as other contaminants that are within this mass range. The peaks were detected, baseline subtracted, calibrated on mass accuracy, clustered by using the software analysis, and peak intensities were compared within the reference ranges.
Enzyme-Linked Immunosorbent Assays
Serum amyloid A. A wash buffer, a substrate solution, and a serum amyloid A (Abazyme, Massachusetts) standard were prepared as directed by the kit. Samples were diluted with a calibrator diluent in a 1:50 ratio. One hundred microliters of the standard or sample solutions were placed in the appropriate antibody-precoated microtiter wells and allowed to incubate for 1 hour. After washing, the conjugate solution was added and allowed to incubate for 1 hour. After a final wash, the substrate solution was added to the wells and allowed to incubate for 15 minutes. Following this, a stop solution was added and the microtiter was measured at 450 nm.
C-reactive protein (ZYMUTEST CRP Hyphen
Biomed, Hyphen BioMed, France). Sample and control plasma was diluted 100-fold in diluent. These solutions were used to prepare standards for the calibration curve. A stepwise procedure included the introductions of anti-H-CRP-Horseradish peroxidase immunoconjugate and the standard solutions in the corresponding micro ELISA wells. The samples were homogenized and incubated for 1 hour at room temperature. Following this, the plates were washed and the substrate was introduced. After 5 minutes of incubation at room temperature, 0.45 mol/L sulfuric acid was added to stop the color development. The plate was allowed to stabilize and the absorbance was measured at 450 nm after 10 minutes.
Tumor necrosis factor a (QUANTIKINE Human TNF a/TNFSF1A, R&D Systems, Minnesota). The reagents were prepared as directed. Assay diluent was added to each well, followed by standard, control, or sample. This was allowed to incubate for 2 hours at room temperature, followed by serial washing. Conjugate was added to each well and allowed to incubate for 2 hours at room temperature, followed by another serial washing. Substrate solution was added and incubated for 20 minutes while protected from light. The stop solution was added and the microtiter was measured at 450 nm.
Tissue factor pathway inhibitor (TFPI ASSERACH-ROM FREE TFPI, Diagnostica Stago, France). Using a 1:10 dilution of given reagents, a working standard solution was prepared. Using this solution, the calibration curves were prepared. The patients' plasma was diluted according to the free TFPI concentration and the quality control dilutions were included in each test. The microtiter plate was allowed to incubate at room temperature and the absorbance was measured at 492 nm.
Results
A typical biomarker profile of plasma samples obtained from a patient who has undergone surgical intervention for hip fracture is shown in Figure 1 . The biomarker profiling depicted in this figure covers a molecular weight of 5 to 25 kd. As can be seen on day À1, there was no detectable signal for a biomarker peak at 11.9 kd. On the first day after surgery, a detectable signal with low intensity (<.25) was observed. On the third day after surgery, the 11.9 peak signal was markedly intensified (>.75). A gradual diminution was noted on days þ5 and þ7. However, even on day þ7, a detectable signal at 11.9 kd was noted. In contrast to the patient sample, the NHP did not have any detectable signal at 11.9 kd. Most of the patients included in this study exhibited this pattern. Figure 2 shows a bar graph on the composite data on the percentage prevalence of the unique biomarker on the presurgical one day prior to surgery (day À1) (7.6%), one day after surgery (day þ1) (80.3%), three days after surgery (day þ3) (87.7%), five days after surgery (day þ5) (50%), and seven days after surgery (day þ7) (17.9). As can be seen that on the þ3 day the percentage prevalence peaked, whereas a gradual diminution was noted on days þ5 and þ7. These data indicated that the 11.9-kd unique biomarker peak is most prevalent on these patients on the third day. Figure 3 depicts the serum amyloid A levels in patients undergoing surgical interventions on 1 day prior to surgery and 3 days after the surgery. As can be seen in comparison to NHP, serum amyloid A levels are much higher in elderly patients presenting with a hip fracture. On the third day after surgery, the serum amyloid A levels were higher (130%) in comparison to the presurgical levels (70%).
The data on the increase in the circulating CRP levels in the elderly patient undergoing orthopedic surgery are shown in Figure 4 . As shown in this figure, a marked scatter in the data was noted for both the presurgical day and day 3 postsurgical samples. There was a sticking increase in the CRP level in the elderly patient with hip fracture in the day before surgery (453%). On the third day after surgery, a modest increase in the CRP level was noted (503%). Figure 5 shows the data on the TNF-a modulation in elderly patients undergoing orthopedic surgery. In comparison to the normal group, the elderly group showed increased levels of plasma TNF-a in the samples collected 1 day prior to surgery (36%). On day þ3 (400%), a marked increase was noted in the TNF-a level, which is comparable to CRP levels.
The data on the TFPI antigen levels are shown in Figure 6 . The samples collected a day prior to surgery showed a slight increase (13%) in comparison to normal individuals. The TFPI levels were markedly increased on the þ3 day (127%) after surgery. There was a wide scatter in the TFPI levels in samples collected on day þ3.
Discussion
In the 29 baseline samples, no unique biomarker was seen compared to pathologic plasma pool and NHP. In the pathologic plasma obtained from previous studies, there was a well-defined biomarker peak at 11.9 kd. 12 Interestingly, the PK-532 samples also showed the unique biomarker around 11.9 kd. On the day prior to surgical intervention, the biomarker was seen only in 7.6% (4 of 52) of the samples. On day 1 postoperatively, 80.3% (41 of 51) showed a distinct peak at 11.9 kd. On day 3, 87.7% (43 of 49) of patients showed the presence of this biomarker often at its strongest intensity. A total of 50% (22 of 44) showed this biomarker on day 5 and 17.9% (4 of 23) on day 7 of the 52 PK-532 samples run. Thus, there was a progressive increase until the third day followed by a decline in the prevalence of this biomarker. Although the identity of the 11.6 to 11.9 peak is not known, it may be related to serum amyloid A or one of its derivatives. The intensity of this peak varied from experiment to experiment, likely depending on various factors from the plasma protein concentration of the individual to the preparation technique of the gold chip. Regardless of this limitation, the 11.6-11.9 peaks represent a unique biomarker profile with a defined time course after surgery in these patients. In the current format, this technique is a qualitative profiling of the biomarker patterns; however, it can be refined to obtain qualitative data.
To further validate the hypothesis that the acute phase response was augmented by surgical intervention, serum amyloid A and 3 other acute phase proteins including CRP, TNF-a, and TFPI were measured using ELISA tests on 30 patients samples, analyzing the changes in optical density from the various proteins in the preoperative samples versus day 3 after intervention. These data were used to compare the patient's plasma levels for each of the parameters.
Enzyme-linked immunosorbent assay analysis showed that serum amyloid A exhibited a 70% increase from normal in these patients after the initial traumatic fracture and prior to surgery. These levels rose to 130% on the third day after surgical intervention. C-reactive protein levels were similarly elevated, 450% above the normal limit upon presentation to the hospital and 500% above normal on the third day after surgical intervention. Tumor necrosis factor a was increased 36% higher than normal levels upon presentation and 400% above normal 3 days after surgical intervention for the hip fracture. Tissue factor pathway inhibitor was up to 15% from the normal at presentation and near 130% on the third day after surgical fixation. The results interpreted here are primarily focused on days À1 and þ3 as these time points represent a more complete set of patient number for comparison.
Consistent with earlier findings seen in orthopedic patients, these results demonstrate that hip fracture in the elderly patients is associated with generation of a unique biomarker at 11.9 kd. 12 The fact that this biomarker is present in the majority of patients in the postsurgical period indicates that it may be an acute phase protein generated from the traumatic hip fracture that is even further augmented by surgical intervention.
Unlike the younger total arthroplasty patients, where the peak was almost exclusively seen on the third day after arthroplasty, in the previous study, the elderly patients demonstrated the peak on day 7 after surgical intervention almost 25% of the time, compared to 2% of the time in the study involving younger patients. 12 This sustained presence of this unique biomarker may be the result of many compounding factors, including the insult of the hip fracture, impaired clearance of the biomarker due to renal or hepatic insufficiency associated with the aging process, or other comorbid conditions. This may represent the first proteomic analysis of hip fracture in elderly patients.
Because these samples were from individuals only treated for 1 week, this study provides unique information about the early phase of pathogenesis in protein regulation initially after hip surgery. This 11.9-kd biomarker likely represents one of the homolog proteins of serum amyloid A, an apolipoprotein that has been shown to increase its production following orthopedic trauma. 9 It has been previously reported that profiling analysis of biomarkers in the molecular mass range of 11.6 to 11.8 were two isoforms of serum amyloid A, as confirmed by tandem mass spectrometry fragmentation.
The modulation of this unique biomarker did not seem to show any apparent differences in appearance or intensity based on treatment of patients with enoxaparin or UFH. The sample size in this study may be too small at this time to accurately predict significance of modulation by enoxaparin or heparin in the patient plasma samples.
Conclusions
The initial studies used for the analysis of acute phase reactants in the inflammatory process on the elderly hip fracture plasma samples confirmed an augmented response to the inflammatory process after surgical intervention. The identified unique protein biomarker at 11.9 kD may offer insight into the pathophsyiology of the early acute phase response in elderly patients. This may lead to a better understanding of increased risk of thrombogenesis including DVT and pulmonary embolism in elderly population. The differences between the inflammatory response biomarkers in younger healthier individuals versus the elderly individuals could be the result of normal physiologic changes as well as confounding comorbidities despite similar prophylaxis. The prolonged generation of these inflammatory biomarkers may offer insight into the increased risk of thromboembolic phenomenon in elderly patients undergoing surgical procedures. Our study may be limited due to the fact that not every patient evaluated using SELDI-TOF mass spectrometry had a plasma sample from the day prior to surgical intervention all the way to the seventh day postoperatively, due to incomplete follow-up of the patients.
Clinical Implications
Surgical interventions have always led to complications of VTE, despite prophylaxis with anticoagulation drugs. With the identification of unique biomarkers that play key roles in the inflammatory/ thrombogenic process, one may be able to better use prophylactic agents and better design new agents to further decrease the risk of VTE following surgical intervention. As the population continues to age, the number of hip fractures will increase due to the various risk factors linked to the elderly individuals. Reducing the number of fatal and nonfatal thromboembolic complications surrounding orthopedic procedures is of increasing importance given the population affected.
